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ABSTRACT 
Nanoencapsulation of antioxidant molecules on protein nanoparticles (NPs) could be an ad-
vanced approach for providing stable, better food nutraceuticals and anticancer drugs. The bi-
oavailability and stability of catechin (CAT) and epicatechin (ECAT) were very poor. In the 
present study, the CAT and ECAT were loaded on bovine serum albumin (BSA) NPs follow-
ing desolvation method. The transmission electron microscope (TEM) and atomic force mi-
croscope (AFM) recorded size of CAT-BSA NPs and ECAT-BSA NPs were 45 ± 5 nm and 
48 ± 5 nm respectively. The encapsulation efficiency of CAT and ECAT on BSA NPs was 
found to be 60.5 and 54.5 % respectively. CAT-BSA NPs and ECAT-BSA NPs show slow 
and sustained in vitro release. The CAT-BSA NPs and ECAT-BSA NPs were stable in solu-
tion at various temperatures 37 °C, 47 °C and 57 °C. DPPH assay revealed that CAT and 
ECAT maintained their functional activity even after encapsulation on BSA NPs. Further-
more, the efficacy of CAT-BSA NPs and ECAT-BSA NPs determined against A549 cell lines 
was found to be improved. CAT and ECAT aptly encapsulated in BSA NPs, showed satisfac-
tory sustained release, maintained antioxidant potential and found improved efficacy. This has 
thus suggested their more effective use in food and nutraceuticals as well as in medical field.  
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INTRODUCTION 
Drug delivery through nanoparticles 
(NPs) is one of the most promising areas of 
nanotechnology. Nanoencapsulation is the 
formation of drug/molecule loaded NPs. 
Nanoencapsulation of drugs on NPs in-
creases their efficacy, protects drug from 
degradation and maintains functional activi-
ty of encapsulated drugs (Reis et al., 2006). 
NPs used widely for drug delivery are fab-
ricated from natural and synthetic macro-
molecules (Yadav et al., 2011; Kumari et 
al., 2010a). Among natural macromole-
cules, proteins have gained attention due to 
biodegradability, lack of toxicity and non-
antigenicity (Moghimi et al., 2001; Patil, 
2003; Maghsoudi et al., 2008). The pres-
ence of charged groups in proteins make 
them suitable matrix for drug entrapment 
(Zhao et al., 2010; Muller et al., 1996). Se-
rum albumin from human and bovine have 
been commonly used for preparation of 
NPs. Albumin can accommodate large 
number of drugs in a non-specific manner 
and it can be prepared in large batches in 
simple and cost effective manner (Zhao et 
al., 2010). Many drugs like 5-fluorouracil, 
paclitaxel and sodium ferulate have been 
encapsulated on BSA NPs for improving 
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their efficacy (Bansal et al., 2011; Li et al., 
2008). 
Bioactive agents such as nutrients, phy-
tochemicals, nutraceuticals, cosmaceuticals 
may be incorporated into NPs to increase 
their efficacy and reduce their side effects 
(Yadav et al., 2013). The tea polyphenols 
catechin (CAT) and epicatechin (ECAT) 
having active hydroxyl groups are im-
portant for treating various diseases (Naga-
rajan et al., 2008) as well as for making an-
ti-ageing beauty products (Maurya and 
Rizvi, 2009) and in food and nutraceutical 
applications. The molecular structures of 
CAT and ECAT are shown in Figure 1. 
Previous studies have reported that ECAT 
exert neuroprotective properties and pre-
vent neuronal cell death, while the CAT is 
reported to be protective against induced 
cardio toxicity in rat (Inniguez-Franco et 
al., 2012). The widely consumed beverage 
tea has anti-tumorgenic, anti-oxidative, an-
ti-mutagenic, anti-pathogenic properties 
due to the presence of CAT and ECAT 
(Maghsoudi et al., 2008; Chu et al., 2004). 
However, the over dose of CAT and ECAT 
for enhancing the bioavailability is not 
good for health and produces side effects 
and lowers the absorption of other bioactive 
molecules (Knekt et al., 1996). Likewise, 
the over consumption of hot tea containing 
CAT is responsible for acidity and prostate 
cancer (Koo and Cho, 2004; Shafique et al., 
2012). 
 
 
 
 
Figure 1: Molecular structures of (a) catechin 
(b) epicatechin  
 
Inspite of wide spectrum biological 
properties of CAT and ECAT, their effec-
tive use is limited due to poor aqueous sol-
ubility, less stability and low bioavailabil-
ity. The bioavailability of both these mole-
cules is as low as 5 % (Catterall et al., 
2003). Also the lack of long term stability 
(Volf et al., 2014), sensitivity to light and 
temperature (Munin and Edwards-Levy, 
2011) are making these molecules unpopu-
lar in pharmaceutical and other industries. 
CAT encapsulated on PLGA NPs showed 
greater ability to scavenge free radicals 
(Pool et al., 2012). CAT encapsulated on 
gelatin NPs retained antioxidant activity 
even after three days of storage (Chen et al., 
2010). NPs are commonly prepared by 
emulsification or desolvation method. But 
emulsification process requires the organic 
solvent removal and surfactant for emulsion 
stability, while desolvation method does not 
require organic solvent and surfactant. To 
overcome the problems of bioavailability, 
stability, self oxidation in water and side ef-
fects of overdose, CAT and ECAT loaded 
BSA NPs were synthesized in this study by 
desolvation method. Synthesized CAT-
BSA, ECAT-BSA and blank-BSA NPs 
were characterised by nanodrop, TEM, 
DLS and FTIR. Encapsulation efficiency 
and drug loading was calculated with the 
help of HPLC. Temperature stability stud-
ies of CAT-BSA and ECAT-BSA NPs were 
also carried out at 37 °C, 47 °C and 57 °C. 
Antioxidant activity of synthesized CAT-
BSA NPs and ECAT-BSA NPs was evalu-
ated with DPPH assay. The efficacy analy-
sis of pure CAT, ECAT and their loaded 
BSA NPs including blank NPs was carried 
out using the A549 cells. 
 
MATERIAL AND METHODS 
Materials  
(+) Catechin and (-) epicatechin were 
purchased from Sigma (USA) and use as 
such. BSA was obtained from the New 
England Bio Lab (UK). The HPLC grade 
methanol and milli Q water were received 
from SD Fine Chemical Limited (India). 
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Absolute ethanol (99.9 %) was purchased 
from Changshu Yanguan Chemical China. 
The A549 (human lung carcinoma cells) 
cells were obtained from NCCS (National 
Centre for Cell Science), Pune and were 
cultured in HAM’S-F-12 (Sigma Aldrich), 
supplemented with 10 % heat inactivated 
fetal bovine serum (Sigma Aldrich) and 
1 % antibiotic antimycotic (Sigma Aldrich). 
Cells were maintained at 37 °C in a 5 % 
CO2 humidified atmosphere. 
 
Preparation of CAT-BSA and ECAT-BSA 
loaded NPs 
The synthesis of CAT and ECAT load-
ed and blank NPs of BSA was conducted 
using desolvation method. BSA (27 mg) 
was dissolved in 1 ml milli Q water in a 
15 ml glass vials on magnetic stirrer at 
37 °C. Absolute ethanol (3 ml) was added 
in 1 ml BSA along with CAT (4 mg) for 
generating the drug loaded NPs. Same 
method was followed for the synthesis of 
blank and ECAT loaded NPs. Gluteralde-
hyde (20 µl) was initially used for cross 
linking and synthesis of NPs. The synthe-
sized NPs were left overnight after covering 
the vials with aluminum foils on magnetic 
stirrer at controlled conditions of 350 rpm 
and 37 °C. Next day, NPs were centrifuged 
at14000 rpm and redissolved in milli Q wa-
ter for further use.  
 
Characterization of synthesized BSA, 
CAT-BSA and ECAT-BSA NPs 
Spectroscopic characterization  
Two µl each of pure CAT, pure ECAT 
and CAT-BSA, ECAT-BSA and BSA NPs 
along with supernatant of CAT loaded BSA 
NPs and ECAT loaded BSA NPs (obtained 
after the removal of NPs by centrifugation) 
were used for spectroscopic analysis. The 
UV–Vis spectrophotometer (Nanodrop ND-
2000 USA) with path length of 1 mm and 
2048 element linear silicon CCD array de-
tector was used for spectroscopic scan 
analysis from 220 to 700 nm using appro-
priate blanks. 
Nicolet 6700 FTIR (Thermo, USA) 
spectrophotometer was used to record the 
IR spectra of pure CAT, pure ECAT and 
their loaded BSA NPs. The KBr pellets 
were prepared using the smart OMNI-
sampler accessory at pressure of 125 Kg/ 
cm2 for 3 min. Samples of IR were properly 
dried in oven for 5 days at 30 °C. The spec-
tra of pure CAT, pure ECAT, CAT-BSA 
and ECAT-BSA NPs were analyzed in the 
scanning range of 400 -4000 cm-1 at 4 cm-1 
resolution. 
Surface morphological characterization  
CAT, ECAT loaded BSA NPs and 
blank BSA NPs were characterized using 
the atomic force microscope (Nanoscope-
III, Veeco Instruments, Singapore). A drop 
of NPs was put on the freshly clean glass 
surface, spread uniformly and left for dry-
ing in dust free conditions. Images were 
taken in tapping mode using silicon probe 
cantilever of 125 µm length, resonance fre-
quency of 209-286 kHz, spring constant of 
20-80 N/m and nominal, 5-10 nm tip radius 
of curvature and scan rate of 1 Hz. Each 
sample (BSA NPs, CAT-BSA NPs and 
ECAT-BSA NPs) was scanned with AFM 
silicon tips and minimum 3 images were 
recorded.  
Finally, the synthesized NPs were char-
acterized by the TEM (FEI, Netherlands) at 
a bias voltage of 200 kV. NPs dissolved in 
milli Q water were put on the carbon coated 
TEM grid and stained with two percent 
ammonium molybdate.  
 
Thermo stability measurement of NPs 
The stability of NPs in water was car-
ried out at three temperatures 37 °C, 47 °C 
and 57 °C up to 72 h. The DLS size and 
zeta potential of blank-BSA NPs and load-
ed CAT-BSA and ECAT-BSA NPs were 
measured on DLS (Zetasizer Nano ZS, 
Malvern Instruments Ltd, UK) using dis-
posable zeta cells. TEM images were rec-
orded on carbon coated copper grid 
(CF300-Cu mesh, Electron Microscopy 
Sciences) using the negative stain ammoni-
um molybdate. 
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Encapsulation analysis of CAT- BSA and 
ECAT- BSA NPs with HPLC 
HPLC (Waters USA, coupled with di-
ode array detector 2998) was used to evalu-
ate the encapsulation efficiency of CAT and 
ECAT molecules on BSA NPs. The super-
natant (10 µl) of synthesized NPs obtained 
after centrifugation at 12000 rpm, was fil-
tered through 0.22 µm membrane and di-
rectly injected in HPLC C18 column 
(150 mm × 4.6 mm, 5µm size) with the 
help of auto sampler (Waters 2707). Meth-
anol and Milli-Q water (75 : 25) containing 
0.1 % TFA were used as mobile phase with 
flow rate 0.8 ml/min at 280 nm. The cali-
bration curves were generated using differ-
ent concentrations of CAT and ECAT. The 
calibration curve of CAT was found linear 
in the range 0.0625 to 1 mg/ml and correla-
tion coefficient was found as 0.999 ± 
0.0002 (Figures S4(a) and (b)). Similarly 
the calibration curve of ECAT was linear in 
the range 0.0625 to 1 mg/ml and correlation 
coefficient was found 1 ± 0.0002 (Figures 
S4(c) and (d)). The regression equation 
generated by calibration curves of CAT 
(Y = 1×107x + 12915) and ECAT (Y= 
1×107x - 25467) were used to calculate the 
encapsulation efficiency. The formulas giv-
en below were used for calculation of the 
encapsulation efficiency (EE) and the drug 
loading. (1) 
100
/
/(%) ×





=
nformulatioinECATCATofamounttotal
entrappedECATCATofamountEE
 
(2) 
100
cov
/(%)/ ×





=
tionlyophilisaaftereredrelesnanoparticofmass
lesnanoparticinentrappedECATCATofmassloadingECATCAT
 
 
In vitro release study of CAT- BSA and 
ECAT- BSA NPs 
The release of CAT and ECAT from the 
NPs, during in vitro conditions was deter-
mined using HPLC. For the study of release 
kinetics, 10 mg CAT-BSA and ECAT-BSA 
NPs were dissolved in 20 ml of 0.1 M 
phosphate buffer saline (pH 7.4). The NPs 
solutions were continuously stirred at 
50 rpm in thermostat to make the uniformi-
ty of NPs in buffer at constant temperature 
(37 °C). After regular intervals of 0, 2, 4, 6, 
8, 12, 18, 24, 30, 36, 42 and 48 h, the sam-
ples were collected (1.0 ml) and lyophi-
lized. The lyophilized samples were re-
dissolved in methanol and centrifuged at 
12000 rpm for 15 min. The samples were 
filtered through 0.22 µm membrane and in-
jected in HPLC to analyze the release of 
CAT and ECAT in the buffer with help of 
calibration curves (Figures S4(a-d)). 
The formula given below was used for 
the calculation of the amount of drug re-
leased at time‘t’ (3) 
100
/
/(%) ×





=
ttimeatECATCATofamounttotal
ttimeatECATCATofamountreleasedreleaseCumulative
 
 
Antioxidant activity analysis of encapsu-
lated NPs  
The 1,1-diphenyl-2-picrylhydrazyl free 
radical (DPPH•) was dissolved in methanol 
(3.9 mg/100 ml). The pure CAT, pure 
ECAT and NPs (ECAT-BSA, CAT-BSA 
and BSA NPs) were incubated with DPPH 
for half an hour in dark. The absorbance 
was recorded by the nanodrop (Nanodrop 
ND-2000 USA) at 517 nm in 2 ml optic 
glass cuvette and three replicates of each 
were used to evaluate the inhibition of 
DPPH. The blank BSA NPs were used as 
negative control and pure compounds 
(CAT/ECAT) were used as positive control. 
The formula given below was used to cal-
culate the percentage of inhibition of DPPH 
by the test compounds pure CAT, pure 
ECAT, blank-BSA, CAT-BSA and ECAT-
BSA NPs. (4) 
100
)(
)()((%) ×




 −
=
controlofAbsorbance
sampleofAbsorbancecontrolofAbsorbanceactivitytAntioxidan
 
 
Efficacy evaluation of BSA, CAT-BSA 
and ECAT-BSA NPs 
The cellular efficacy of pure molecules 
vis-à-vis their encapsulated form was 
measured using the sulforhodamine B 
(SRB) method. Viable cells were seeded in 
the growth medium (100 μL) into 96 well 
microtiter plates (2×104 cells per well) and 
allowed to adhere overnight. The test com-
pounds were dissolved in culture media and 
DMSO following 1:1 ratio respectively. 
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Several dilutions starting from 50, 100, 150, 
and 200 μg/ml of CAT-BSA and ECAT-
BSA NPs in 100 μl of complete medium 
were added to the selected wells. After dilu-
tion the plates were incubated at 37 °C for 
24, 48 and 72 h using 5 % CO2 incubator. 
After incubation period, 50 μL of 50 % tri-
chloroacetic acid was added to the wells 
and then the plates were incubated at 4 °C 
for one hour. The TCA treated cells were 
washed 3 to 4 times with water and allowed 
to air dry. Subsequently, 100 μl of the SRB 
solution containing 1 % acetic acid was 
added to each well at room temperature. 
After standing for 30 min, the wells were 
washed 3 to 4 times with 1 % acetic acid 
and left for air dry. The bound dye was dis-
solved in 10 mM tris base (100 Μl / well). 
The absorbance was measured using micro-
plate reader (BioTeK Synergy H1 Hybrid 
Reader) at wavelength of 540 nm. The per-
centage growth inhibition was calculated 
using the following formula: (5) 
100
)((
)()(100(%) ×





−
−
−=
AbAc
AbAtinhibitionCell
 
where Ab, Ac and At are absorbance value 
of blank, control and test compounds re-
spectively. 
 
RESULTS AND DISCUSSION 
Loading of CAT and ECAT in BSA NPs  
CAT and ECAT loaded BSA NPs were 
prepared by desolvation method. Desolva-
tion is a thermodynamically driven self as-
sembly process for proteins to form NPs. 
Size of NPs is controlled by varying protein 
content, pH, ionic strength, concentration of 
cross linking agent and amount of desolvat-
ing agent (Jun et al., 2011). This is a simple 
method for the synthesis of BSA NPs and 
there is no need of surfactants for capping 
the NPs surface. Also, size of BSA NPs can 
be controlled with this method (Zambaux et 
al., 1999). BSA was dissolved in milli Q 
(1 ml) water using magnetic stirrer. The 
ethanol containing CAT was added drop 
wise in BSA solution. This addition pro-
duced turbidity in reaction solution and re-
sulted into the appearance of catechin-
loaded BSA NPs in the solution. Ethanol 
acts as anti-solvent for BSA to reduce its 
solubility in water and facilitate NP for-
mation by precipitation. NPs formed were 
crosslinked by glutaraldehyde. BSA has 
previously been used as synthesis materials 
for NPs and delivery of bioactive molecule 
(Xie et al., 2012). The synthesized NPs of 
CAT were separated and easily redispersed 
in the distilled water. Similarly ECAT load-
ed BSA NPs and blank BSA NPs were syn-
thesized in solution form (Figure S1(k)). 
The dried CAT-BSA and ECAT- BSA and 
BSA NPs were stored at room temperature 
for further study. 
 
Characterization of CAT-BSA and ECAT-
BSA NPs 
Spectroscopic characterization of CAT-BSA 
and ECAT-BSA NPs 
UV–Vis spectrum is used for initial 
screening of synthesis of NPs (Yogasunda-
ram et al., 2012). UV-Vis spectroscope ND 
1000 was used to characterize the CAT and 
ECAT loaded BSA NPs. The UV-Vis char-
acterization of BSA NPs gave a characteris-
tic absorption peak at 230 nm and provided 
initial information about the synthesis of 
CAT-BSA NPs (Figure 2(a)) and ECAT-
BSA NPs (Figure 2(b)).  
FTIR spectroscopy was used to reveal 
the encapsulation of CAT and ECAT on 
BSA. The IR spectroscopy is not only used 
for the study of protein-protein interaction 
or with other molecules (Haris, 2010), but 
also used to analyze the encapsulation of 
bioactive molecules on the NPs. The IR 
spectroscopic analysis was used in the ear-
lier study as well for the characterization of 
BSA NPs (Sailja and Amareshwar, 2012). 
The pure compounds CAT (Figure 3(a)) 
and ECAT (Figure 3(b)) and encapsulated 
CAT-BSA NP (Figure 3(c)) and ECAT-
BSA NP (Figure 3(d)) were scanned using 
IR spectroscopy. The appearance of strong 
intensity bands at 3409.4, 3219.5 cm-1 rep-
resents -OH group, strong intensity bands at 
1633.4, 1515.3 cm-1 represents aromatic C= 
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C group, and medium intensity bands at 
1143.5, 1019.7 cm-1 represents C-O-C 
group. The FTIR peaks of CAT loaded on 
BSA are in agreement with the IR spectra 
reported earlier for CAT, showing the char-
acteristic absorption regions for -OH group 
(3400 – 3100 cm-1), C = C group around 
1600 cm-1, as well as C-O-C group (1150 – 
1010 cm-1) (Maoela et al., 2009). The IR 
spectrum documented the loading of CAT 
in BSA NPs without any chemical interac-
tion (Figure 3(c)). Similarly, the appearance 
of strong band at 3400.0 cm-1 represents -
OH, strong intensity bands at 1653.9, 
1523.4 cm-1 represents aromatic C = C, and 
medium intense bands at 1143.2 and 
1094.7 cm-1 represents C-O-C (Figure 
3(d)). The FTIR peaks of ECAT loaded on 
BSA are in agreement with the IR spectra 
reported earlier for ECAT, showing the 
characteristic absorption regions for -OH 
group (3362 cm-1) and C = C groups (1600- 
1450 cm-1) (Li et al., 2007). The IR spec-
trum documented the loading of ECAT in 
BSA NPs without any chemical interaction. 
FTIR has been used earlier in the study of 
conformational changes in albumin-gold 
nanoparticle bioconjugates (Shang et al., 
2007). Also, the nanoencapsulation of bio-
active molecules like quercetin and quer-
citrin on NPs have also been confirmed us-
ing FTIR (Kumari et al., 2010b, 2011). 
Morphological characterization of CAT-
BSA and ECAT-BSA NPs 
NPs < 100 nm are of special interest for 
drug delivery. Size of NPs affects release 
rate, solubility and dissolution rate of a 
molecule/drug (Dufort et al., 2012). The 
targeting, stability, biocompatibility, and in-
filtration of the NPs inside the cellular tis-
sues are also governed by the morphology 
and size of nanomaterials (Albanese et al., 
2012). Smaller sized NPs are retained in 
systemic circulation for longer duration as 
compared to larger NPs (Nel et al., 2009). 
NPs undergo distribution to different organs 
of the body in size and shape dependent 
manner (Huang et al., 2010). 
Size of CAT-BSA and ECAT-BSA NPs 
was measured by AFM and TEM. Blank 
BSA NPs were round, and spherical in na-
ture (Figure 4(a)). AFM images revealed 
that surface morphology of the CAT-BSA 
NPs were round, smooth to polygonal (Fig-
ure 4(b)), while those of ECAT-BSA NPs 
were only round (Figure 4(c)). The CAT 
and ECAT loaded BSA NPs did not show 
aggregation (Figure 4(b) and 4(c)). Similar 
morphological characteristics have been re-
ported earlier for CAT loaded PLGA and 
CAT loaded gelatin NPs (Pool et al., 2012; 
 
Figure 2: (a) UV–Vis spectra of pure catechin (CAT) and catechin-bovine serum albumin nanoparti-
cles (CAT-BSA NPs) and catechin-bovine serum albumin (CAT-BSA) supernatant solution (left after 
the removal of synthesized CAT-BSA NPs), (b) UV–Vis spectra of pure epicatechin (ECAT), epicate-
chin-bovine surum albumin nanoparticles (ECAT-BSA NPs) and epicatechin-bovine serum albumin 
(ECAT-BSA) supernatant solution (left after the removal of synthesized ECAT-BSA NPs).  
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Figure 3: FTIR chromatogram of (a) pure catechin (CAT), (b) pure epicatechin (ECAT), (c) catechin-
bovine serum albumin nanoparticles (CAT-BSA NPs), (d) epicatechin-bovine serum albumin nanopar-
ticles ECAT-BSA NPs 
 
 
 
Chen et al., 2010). TEM was used for fur-
ther morphological characterization of NPs. 
The CAT-BSA and ECAT-BSA NPs 
were smaller in size than blank-BSA NPs 
size (62 ± 10 nm) (Figure 4(d)). The aver-
age size of the CAT-BSA NPs and ECAT-
BSA NPs were 45 ± 5 (Figure 4(e)) and 48 
± 5 nm (Figure 4(f)), respectively. The syn-
thesized NPs were smooth, and spherical in 
shape. DLS was used to measure the zeta 
potential of CAT-BSA, ECAT-BSA and 
blank-BSA NPs. Zeta potential of CAT-
BSA, ECAT-BSA and blank-BSA NPs 
were -34.6, -22.5 and -32.6 mV respective-
ly. 
Previous study has reported the for-
mation of 410 nm size NPs of CAT with 
PLGA (Chen et al., 2010). However; in this 
study we could synthesize CAT-BSA and 
ECAT-BSA NPs of the size below 50 nm. 
Hence, these may find better potential for 
medical applications in comparison to the 
earlier reported CAT NPs on PLGA.  
 
 
Figure 4: Shape and size analysis of blank-
bovine serum albumin nanoparticles (BSA 
NPs), catechin-bovine serum albumin nanopar-
ticles (CAT-BSA NPs) and epicatechin-bovine 
serum albumin nanoparticles (ECAT-BSA NPs). 
Atomic force microscope (AFM) images of (a) 
blank-BSA NPs, (b) CAT-BSA NPs, (c) ECAT-
BSA NPs. Transmission electron microscope 
(TEM) images of (d) blank- BSA NPs, (e) CAT-
BSA NPs, (f) ECAT-BSA NPs 
 
 
EXCLI Journal 2014;13:331-346 – ISSN 1611-2156 
Received: January 31, 2014, accepted: February 27, 2014, published: April 01, 2014 
 
 
338 
Nanoencapsulation provided thermostable 
and maintained antioxidant potential of 
CAT and ECAT in CAT-BSA and ECAT-
BSA NPs 
NPs stability is classified in terms of 
chemical stability, pharmaceutical stability, 
and physical stability. Although the phar-
maceutical stability (Muthu and Feng, 
2009) and chemical stability (Avgoustakis 
et al., 2002) have been assessed and differ-
ent degradation mechanisms have been 
identified depending on NPs dimensions 
and polymer reactivity (von Burkersroda et 
al., 2002). The colloidal stability of NPs is 
still remained poorly investigated (Madlova 
et al., 2009). In the present study, physical 
stability of CAT-BSA, ECAT-BSA and 
BSA NPs was assessed in solution using the 
Zeta sizer and TEM at three temperatures 
37 °C, 47 °C and 57 °C. The shape and sur-
face morphology of NPs in solutions at dif-
ferent temperatures was monitored by TEM 
after 24, 48 and 72 h of incubation. 
Earlier, BSA has been used as a stabi-
lizer agent for the synthesis of stable nano-
formulations of gold, silver and their alloy 
NPs (Singh et al., 2005). Zeta potential is a 
good indicator of physical stability of NPs 
(Kumari et al., 2012). Zeta potential values 
of CAT-BSA and blank-BSA NPs were de-
creased from -35.8 mV to -24.8 mV and -
36.2 mV to -25.2 mV (Figure 5(a)) respec-
tively after 72 hours of incubation at 37 °C. 
Temperature and light have also been re-
ported earlier to decrease the zeta potential 
of solid lipid NPs (Freitas and Müller, 
1998). However, the DLS size of the CAT-
BSA and blank-BSA NPs was decreased 
from 187.2 nm to 176.2 nm and 250.6 to 
229.7 nm (Figure 6(a)) respectively. The 
surface charge of ECAT-BSA NPs was in-
creased from -46.3 mV to -48 mV (Figure 
5(a)) within 48 h and then it become stable 
upto 72 h of incubation at 37 °C. A small 
reduction in size of ECAT-BSA NPs was 
observed after 72 h of incubation compared 
to blank-BSA NPs (Figure 6(a)). Still, the 
synthesized NPs were found to maintain 
their physical integrity and shape revealed 
by TEM recorded pictures (Figure S1).  
Further the solution stability of NPs was 
checked at 47 °C. The size of blank as well 
as loaded NPs was reduced (Figure 6(b)) 
and surface charge was found to be re-
mained stable (Figure 5(b)). The zeta poten-
tial of ECAT- BSA NPs was decreased to -
36.8 from -46.2 mV at 47 °C (Figure 5(b)). 
The stability of NPs was also analyzed at 
higher temperature 57 °C for 3 days. The 
surface charge and size of NPs (blank and 
encapsulated NPs) were slightly changed in 
DLS analysis. However, the particles were 
observed to maintain their size and shape in 
TEM recorded pictures (Figure S3). The 
recorded size of NPs with TEM and DLS 
was different as reported in earlier study 
(Ma et al., 2012). DLS measures the hydro-
dynamic size of NPs. Hydrodynamic size 
tells about inorganic core along with coat-
ing material or the solvent layer attached to 
the NPs surface. While in dried NPs the hy-
dration layer is not present and TEM meas-
ure the core of NPs. Hence, the hydrody-
namic diameter is always greater than the 
actual size recorded by TEM (Ma et al., 
2012). 
The recorded pictures of CAT-BSA, 
ECAT-BSA and BSA NPs showed no sign 
of degradation and maintain their physical 
stability even after 72 h at 37 °C (Figure 
S1), 47 °C (Figure S2) and 57 °C (Figure 
S3). The surfactants sodium dodecyl sulfate 
(SDS), polyoxyethylenesorbitane monoole-
ate (Tween 80) and polymer polyvinylpyr-
rolidone (PVP 360) have been reported to 
be altering the stability and surface of NPs 
(Kvıtek et al., 2008). Since CAT-BSA and 
ECAT-BSA NPs were synthesized without 
any of these surfactants use, they showed 
physical stability. 
The CAT and ECAT get oxidized very 
quickly, leading to progressive appearance 
of a brown colour and unwanted odors with 
a considerable loss in antioxidant activity 
(Bark et al., 2011). Nanoencapsulation of 
CAT on chitosan tripolyphosphate NPs has 
been reported to maintain antioxidant activ-
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ity even after 24 h, while free CAT degrad-
ed in 8 h (Dube et al., 2010). To check the 
oxidation of nanoencapsulated CAT and 
ECAT on BSA NPs, the dissolved NPs 
were analyzed for their color. There was no 
change in the color of CAT-BSA NPs and 
ECAT-BSA NPs (Figure S1(k)); while the 
pure CAT and ECAT were found to be oxi-
dized within a day and their color was 
changed from transparent to light yellowish 
(Figure S1(j)). The bound molecules with 
NPs were not oxidized whereas the un-
bound molecules in supernatant of CAT-
BSA NPs and ECAT-BSA NPs were oxi-
dized within 24 h (Figure S1(l)). Hence, 
nanoencapsulation might have provided 
protection to CAT and ECAT molecules 
from oxidation (Figure S1(k)). These re-
sults have proved that CAT and ECAT in 
the BSA NPs were stable at higher tempera-
ture for longer duration compared to pure 
CAT and ECAT. It might be protecting the 
bioactive molecules inside the tissue during 
temperature rise. This study further re-
vealed that the molecules which are tem-
perature sensitive can be delivered inside 
the body by encapsulating on the BSA NPs. 
It will minimize the chance of drug degra-
dation as temperature rises in the body dur-
ing hyperpyrexia (McGugan, 2001). 
 
Analysis of CAT and ECAT loading in 
BSA NPs 
The encapsulation efficiency depends 
on type of methods, type of molecule, en-
capsulating materials (synthetic and natu-
ral) and medium of NPs synthesis (Elzogh-
by et al., 2012). The encapsulation efficien-
cy (EE) of CAT and ECAT on BSA NPs 
was carried out using the modified validat-
ed HPLC method (Li et al., 2012). The EE 
was calculated by formula 1. The EE of 
CAT was found 60.5 %, while that of 
ECAT-BSA NPs was 54 %. The unbound 
drug appeared in supernatant was detected 
by HPLC (Figure S5).  
As chemical structures of the two mole-
cules are different in stereochemistry, it 
could produce difference in EE on BSA 
NPs. The loading of CAT and ECAT on 
BSA NPs was calculated using formula 2 
and found 12.73 % for CAT and 10.9 % for 
ECAT. On the other hand the EE of 9-
nitrocamptothecin on PLGA NPs has been 
reported more than 30 % (Derakhshandeh 
et al., 2007). Gemcitabine has been loaded 
in BSA-PLGA (dl-lactide-co-glycolide) 
based core-shell NPs with an EE of 40.4 % 
(Chitkara and Kumar, 2013). The reported 
EE of doxorubicin was 88.24 % in cationic 
albumin NPs and was achieved by desolva-
tion method (Abbasi et al., 2012). Hence,  
 
 
 
Figure 5: Zeta potential of blank-bovine serum 
albumin nanoparticles (BSA NPs), catechin-
bovine serum albumin nanoparticles (CAT-BSA 
NPs) and epicatechin-bovine serum albumin 
nanoparticles (ECAT-BSA NPs) at different 
temperatures (a) 37 °C; (b) 47 °C; (c) 57 °C 
 
 
Figure 6: The DLS size of blank-bovine serum 
albumin nanoparticles (BSA NPs), catechin-
bovine serum albumin nanoparticles (CAT-BSA 
NPs) and epicatechin-bovine serum albumin 
nanoparticles (ECAT-BSA NPs) at different 
temperatures (a) 37 °C; (b) 47 °C; (c) 57 °C 
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the low EE of both the molecules CAT and 
ECAT in BSA NPs compared to various re-
ported molecules could be attributed to 
their chemical nature. From nanobiotech-
nology perspective, the observed EE is still 
good for such easily oxidisable/degradable 
molecules. 
 
In vitro release of CAT-BSA and ECAT-
BSA NPs 
The release of drugs depends upon the 
biodegradable nature of polymer, thermo-
dynamic compatibility between polymers 
and drugs, nature of matrix, dilution of re-
leasing medium and the interaction of en-
capsulated molecules with the nanomateri-
als (Park et al., 2005). Encapsulation of 
drugs on the NPs synthesized from such bi-
odegradable polymers can easily control the 
rate of drug released, and the drug concen-
tration (Kamaly et al., 2012). The release 
kinetics of drug changes when temperature 
and pH of releasing medium are altered and 
resulted pattern of release profile may be 
different from the physiological conditions 
(Bennet et al., 2012). The sustained release 
of drug from the NPs protects the drug from 
its fast metabolism and degradation 
(Kamaly et al., 2012). 
In vitro release study of CAT-BSA, 
ECAT-BSA and BSA NPs was carried out 
in PBS and calculated using formula 3. The 
release kinetics of both the molecules was 
studied up to 48 hours (Figure 7, Figure 
S6). Initially for two hours the release of 
CAT was 10.5 %, while the release of 
ECAT was 29.2 % from the NPs in PBS. 
Rapid initial release is attributed to the frac-
tion of the CAT and ECAT adsorbed or 
weakly bound to the large surface area of 
the NPs. Interestingly, the release of CAT 
from BSA NPs was increased to 35.6 % af-
ter 4 h whereas there was no change in re-
lease of ECAT upto 4 h of release. 
The methods of drug incorporation in 
NPs have been reported to influence the re-
lease kinetics (Yoo et al., 1999). The drug 
adsorbed in the NPs has been reported to 
burst release up to 60-70 % followed by the 
remaining quite slow release. The chemi-
cally conjugated drugs in polymeric NPs 
have shown sustained release over many 
days (Fresta et al., 1995). The release pro-
file of ECAT was slow between 8 to 12 h 
followed by fast release of molecules in re-
lease medium. Nature of polymer matrix al-
so has influenced on the distribution of drug 
in NPs and their release (Niwa et al., 1993). 
The maximum release of CAT was 79 % 
after 42 h and that of ECAT was 75 % af-
ter18 h. Earlier studies also reported similar 
release of bioactive molecules from the 
BSA NPs (Fang et al., 2011; Abbasi et al., 
2012). Folate-conjugated albumin NPs have 
been reported for slow release of etoricoxi-
band upto 72 h (Bilthariya et al., 2013). 
HSA NPs loaded with noscapine have been 
reported for 60 % release after 72 h (Sebak 
et al., 2010). BSA NPs were found to be 
capable of releasing CAT and ECAT in 
slow and sustained manner. The CAT and 
ECAT release from NPs follows prolonged 
and two phase release kinetics. Initial burst 
phase followed by slow and sustained 
phase. Initial burst phase is due to the CAT 
and ECAT physically adsorbed on the sur-
face of BSA NPs. The CAT and ECAT 
bound in the core of BSA NPs were re-
leased in a slow and sustained manner. As-
pirin loaded BSA NPs have also been re- 
 
 
 
Figure 7: The release curve of catechin (CAT) 
and epicatechin (ECAT) using high perfor-
mance liquid chromatography (HPLC) by plot-
ting % cumulative release vs time. Values are 
the mean of three biological replicates ± stand-
ard error. 
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ported for similar two phase release (Das et 
al., 2005).The release profile of both the 
molecules supported the use of synthesized 
nanomaterials for both in vitro and in vivo 
conditions.  
 
Retention of antioxidant activity CAT, 
ECAT upon encapsulation on BSA NPs 
DPPH (1,1-diphenyl-2-picrylhydrazyl) 
is a stable free radical containing spare 
electrons delocalization over the whole 
molecule. This electron delocalization gives 
a deep violet colour to it characterized by 
an absorption band at about 517 nm 
(Molyneux, 2004). The loss of this violet 
color is observed when a solution of DPPH 
is mixed with that of a molecule that can 
donate a hydrogen atom. The percentage of 
inhibition of DPPH was calculated by for-
mula 4. 
The CAT and ECAT are well known 
antioxidant molecules and used in food co-
coa, vinegar and glycemic control (Zheng et 
al., 2013; Soobrattee et al., 2005; Amic et 
al., 2003). The solution of antioxidant mol-
ecules CAT and ECAT were incubated with 
DPPH, acting as a hydrogen atom donor, 
and thus a stable non-radical form of DPPH 
was obtained with simultaneous change 
from violet color to pale yellow and ab-
sorbance was decreased (Figure 8(a)). The 
CAT and ECAT contain labile hydrogen 
atoms and by liberation of these hydrogen 
atoms DPPH inhibition was obtained. This 
has also converted unstable CAT/ECAT in-
to stable quinine moiety (Figure 8(b)). The 
lower inhibition of DPPH by the CAT BSA 
and ECAT BSA NPs compared to their un-
encapsulated analogue might be due to slow 
release of loaded molecules during the in-
cubation period in dark or encapsulation 
might have hindered the availability of hy-
drogen radicals and provided protection to  
 
 
 
 
Figure 8: (a) Relative free radical scavenging potential of catechin (CAT), epicatechin (ECAT), cate-
chin-bovine serum albumin (CAT-BSA) and epicatechin-bovine serum albumin (ECAT-BSA) by 2,2-
Diphenyl-1-picrylhydrazyl (DPPH) assay. Upon encapsulation, the antioxidant activity of CAT and 
ECAT was slightly reduced in comparisons to pure CAT and ECAT. Active hydroxyl groups on CAT 
and ECAT quenched the free radical of DDPH turning its deep violet color to pale yellow. (b) the anti-
oxidant mechanism of CAT/ECAT 
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CAT and ECAT from being oxidized. 
DPPH assay has been used earlier to evalu-
ate the antioxidant activity of encapsulated 
molecules. The antioxidant activities of es-
sential oil eugenol and carvacrol-grafted 
chitosan NPs have been reported using 
DPPH assay (Chen et al., 2009). Similarly, 
the antioxidant activity of quercitrin encap-
sulated in PLA NPs was assessed by DPPH 
assay (Kumari et al., 2011).  
 
Efficacy of CAT and ECAT loaded BSA 
nanoparticles  
Drug resistance is a major reason be-
hind the treatment failure in several types of 
cancer including lung cancer (Sadhukha et 
al., 2013). Cell exhibits drug resistance 
which is governed by noncellular and cellu-
lar mechanisms (Andrew et al., 2006). Due 
to the multi-drug resistance the convention-
al drug delivery methods exhibit generally 
lower toxicity. The nanotechnology aspects 
like nanoencapsulation, liposomes, micro-
spheres and targeted delivery could be use-
ful to overcome the drug resistance and also 
enhance the efficacy of bioactive molecules 
(Davda and Labhasetwar, 2002). Therefore, 
this technology could be of great clinical 
significance because many bioactive mole-
cules have low therapeutic indices. 
Also the pay load of molecules in NPs 
should not be altered. It is necessity to 
maintain the functional values even after 
loading of molecules for such nano delivery 
systems (Brzoska et al., 2004; Yadav et al., 
2013). The loaded CAT and ECAT main-
tained their functional activity after the en-
capsulation and in vitro release from BSA 
NPs. SRB assay was carried out to evaluate 
the efficacy of pure CAT, pure ECAT, 
CAT-BSA NPs, ECAT-BSA NPs and blank 
BSA NPs at various concentrations 50, 100, 
150 and 200 µg/ml against A549 cells for 
24, 48 and 72 h (Table 1). The percentage 
cellular inhibition was calculated by meas-
uring the absorbance of respective incubat-
ed cells in the 96 well plates using formula 
5. The CAT-BSA NPs showed maximum 
inhibition of A549 cells by 63.5 % at 
50 µg/ml concentration while ECAT- BSA 
NPs showed maximum inhibition by 
50.6 % at 200 µg/ml concentration after 
72 h of incubation. 
The pure CAT and ECAT have shown 
concentration dependent activity. Pure CAT 
and ECAT were observed to be inhibiting 
the growth of A549 cells to a lower extent 
in comparison to the CAT-BSA NPs and 
ECAT-BSA NPs. Among NPs, the efficacy 
of CAT-BSA NPs was found to be higher 
than ECAT-BSA NPs. The cellular efficacy 
study indicates that both the molecules have 
maintained their functional activity and 
showed greater inhibition of A549 cells af-
ter nanoencapsulated in BSA NPs. 
 
CONCLUSIONS 
In the current study, homogeneous CAT 
and ECAT encapsulated BSA NPs of less 
than 50 nm sizes were produced through 
desolvation method. The encapsulated 
CAT-BSA and ECAT-BSA NPs showed 
slow and sustained release of CAT and 
ECAT. Also, the BSA nanoencapsulation 
has been found to be improving the stability 
of these molecules at higher temperatures 
for longer duration. CAT-BSA and ECAT-
BSA NPs show improved scavenging activ-
ity and efficacy of loaded molecule against 
A549 cells. This study has thus documented 
the potential use of CAT and ECAT in food 
and nutraceuticals as well as medical field. 
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Table 1: Comparative in vitro efficacy of pure CAT, pure ECAT, CAT-BSA NPs, ECAT-BSA NPs and 
blank BSA NPs against A549 cells. Values are the mean of three biological replicates ± standard error. 
Sample Concentration (µg/ml) 
A549 (% Growth Inhibition with SD#) 
24 h 48 h 72 h 
Pure CAT 
50 19.7 ± 3.5 8.6 ± 2.1 11.6 ± 4.0 
100 28.5 ± 1.0 11.2 ± 4.1 18.4 ± 2.4 
150 22.0 ± 2.9 16.2 ± 2.4 12.9 ± 3.1 
200 29.1 ± 4.8 20.8 ± 3.8 27.5 ± 2.5 
Pure 
ECAT 
50 24.4 ± 1.9 10.5 ± 0.3 9.3 ± 4.3 
100 25.0 ± 4.1 7.0 ± 2.9 17.8 ± 3.4 
150 14.5 ± 1.9 10.6 ± 2.4 9.2 ± 5.0 
200 21.0 ± 3.1 17.7 ± 2.7 31.5 ± 2.9 
CAT NPs 
50 6.4 ± 0.4 35.1 ± 1.1 63.5 ± 1.1 
100 14.5 ± 3.1 32.2 ± 3.1 31.7 ± 2.8 
150 12.5 ± 2.9 7.9 ± 3.1 21.5 ± 0.8 
200 22.2 ± 3.7 15.6 ± 1.2 56.4 ± 2.9 
ECAT 
NPs 
50 7.9 ± 4.3 35.1 ± 2.1 3.9 ± 1.8 
100 4.5 ± 3.6 32.2 ± 0.4 6.7 ± 4.4 
150 3.1 ± 3.4 7.9 ± 2.4 15.6 ± 2.0 
200 16.4 ± 1.9 15.6 ± 0.8 50.6 ± 1.6 
Blank 
BSA NPs 
50 2.7 ± 1.3 17.9 ± 0.4 14.6 ± 3.4 
100 2.8 ± 3.3 0.4 ± 2.3 2.0 ± 1.6 
150 0.0 ± 4.2 0.0 ± 1.7 0.0 ± 2.9 
200 8.4 ± 3.4 27.4 ± 4.2 42.0 ± 2.6 
Vinblastin (1µM) 65.7 ± 2.3 74.9 ± 1.8 84.8 ± 1.4 
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